Developer docs
API playgroundTry for free, no card

Search company profiles

Cutiss

Full company profile

uuid0000289

Namestring
Cutiss
Legal namestring
CUTISS AG
Websiteurl
cutiss.swiss
Company typeenum
Private
Founded yearint
2017
Descriptiontext

CUTISS AG is a late-stage clinical TechBio company, spun out of the University of Zurich's Tissue Biology Research Unit in 2017, that develops personalized bioengineered skin grafts for patients requiring skin surgery. Its lead product, denovoSkin™, is a living, bilayer (dermal and epidermal) human skin graft produced from a small patient biopsy and expanded to cover large wound areas, with demonstrated near-scarless regeneration, donor-site sparing, and the ability to grow with pediatric patients. The product is classified as an Advanced Therapy Medicinal Product (ATMP) and has received Orphan Drug Designation from Swissmedic, the EMA, and the FDA for the treatment of burns. The company operates a GMP-certified manufacturing facility in Zurich-Schlieren and is currently running a Phase 3 confirmatory study in adolescent and adult severe burn patients across more than 20 specialized hospitals in Switzerland and 8 EU member states.

The company's strategic moat rests on three reinforcing layers. First, a proprietary tissue-engineering process — including automated cell isolation, expansion, and skin-tissue formation — protected by multiple granted U.S. patents and embodied in the denovoCast™ automation platform, which is being industrialized through a strategic partnership with Tecan. Second, a regulatory moat via Orphan Drug Designation across three jurisdictions and an exclusive global license from IBSA Pharma to commercialize VitiCell®, an MDD CE-marked medical device for autologous cell grafting in vitiligo and hypochromatic post-traumatic scars. Third, a distribution moat built through clinical trial site relationships, compassionate-use engagements with leading U.S. centers such as Massachusetts General Hospital and Shriners Children's Boston, and a collaboration agreement with the Dutch burn center Rode Kruis Ziekenhuis to establish a future international production facility in the Netherlands.

CUTISS is a privately held, pre-revenue company that has raised over CHF 130 million across multiple funding rounds, including a CHF 56 million Series C closed in September 2025. Its go-to-market is enterprise field sales targeting hospital procurement channels for ATMPs, with planned future channels through specialized burn centers and reconstructive surgery departments in Switzerland, the EU, and the United States. The leadership team is led by CEO and co-founder Dr. Daniela Marino; in June 2026, former Tecan Group CEO Dr. Achim von Leoprechting was elected Chairman, succeeding co-founder Prof. Martin Meuli, signaling a deliberate shift toward commercial-scale operating discipline ahead of the expected end-2026 Phase 3 readout and subsequent regulatory submissions.

Short descriptiontext

CUTISS is a late-stage clinical Swiss biotech developing personalized bioengineered bilayer skin grafts (denovoSkin™) for severe burns and reconstructive surgery, supported by the denovoCast™ automation platform and a vitiligo device (VitiCell®), serving burn centers and reconstructive surgery hospitals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSchlieren, Switzerland
HQ citystring
Schlieren
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regenerative skin therapy, bioengineered skin grafts, tissue engineering ATMP, burn wound treatment, personalized cell therapy
Industry3 codes
PRIMARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHALAD
Wound Closure & Securement (Sutures, Staples, Tissue Adhesives, Skin Closure Strips)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAAAKAB
Drug Product Fill-Finish & Aseptic Manufacturing Services
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Regenerative Medicine / Tissue Engineering
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1denovoSkin Product Sales
TypeOne Time License
Description

Once regulatory approval is obtained, the company will generate revenue through the sale of denovoSkin as an ATMP (Advanced Therapy Medicinal Product) to hospitals and burn centers for treatment of severe burns and reconstructive surgery. Revenue will be derived from hospital procurement channels.

cutiss.swiss
2VitiCell Commercialization
TypeOne Time License
Description

CUTISS holds exclusive global rights to commercialize VitiCell, an MDD CE-marked medical device for skin re-pigmentation. Revenue will be generated upon EU MDR CE marking approval through dermatology and hospital channels.

cutiss.swiss
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Operations, Personnel, Supply Chain, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1denovoSkin
Description

Personalized bio-engineered dermo-epidermal skin graft for treatment of burns and reconstructive surgery. A living, bilayer skin graft composed of both epidermis and dermis that can be produced from a small patient biopsy.

cutiss.swiss
+2 more records
Core offering1 text field

CUTISS develops and manufactures personalized, bioengineered dermo-epidermal (bilayer) human skin grafts (denovoSkin™) classified as Advanced Therapy Medicinal Products (ATMPs), produced from a small patient biopsy and expanded to cover large wound areas for treatment of severe burns and reconstructive surgery. The company operates in-house GMP-certified manufacturing in Zurich and is industrializing a patented closed automation platform (denovoCast™) to enable decentralized, scalable production. CUTISS also holds exclusive global rights to commercialize VitiCell®, a CE-marked medical device for autologous cell grafting in vitiligo patients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Significantly better scar quality than standard of care (STSG) at 3 months, maintained at 12 months
+3 more records
Product overview1 text field

CUTISS is a late-stage clinical TechBio company pioneering skin tissue therapeutics and bioengineering. The company's core product is denovoSkin™, a personalized, bio-engineered bilayer (dermal-epidermal) human skin graft for burns and reconstructive surgery. Supporting the core product is denovoCast™, an automation platform for scalable, decentralized production of personalized skin tissue. Additionally, CUTISS commercializes VitiCell®, a CE-marked medical device for skin re-pigmentation in vitiligo patients, licensed from IBSA Pharma. The company operates in-house GMP manufacturing capabilities and is industrializing its automation platform in partnership with Tecan for large-scale production.

Product and service3 records
1denovoSkin™
CategoryAdvanced Therapy Medicinal Product (ATMP) - Bioengineered Skin Graft
Description

Personalized, bioengineered dermo-epidermal (bilayer) human skin graft composed of both dermis and epidermis, manufactured from a small biopsy of the patient's own healthy skin and expanded to produce large quantities of new skin. Classified as an Advanced Therapy Medicinal Product (ATMP) for the treatment of severe burns and reconstructive surgery indications, demonstrating near-scarless regeneration, donor site sparing, and growth with pediatric patients.

2VitiCell®
CategoryMedical Device - Dermatology / Cell Grafting
Description

MDD CE-marked medical device for autologous cell grafting enabling skin re-pigmentation in patients with stable vitiligo and hypochromatic post-traumatic scars. CUTISS holds exclusive global rights to commercialize VitiCell® licensed from IBSA Pharma.

3denovoCast™
CategoryAutomated Tissue Manufacturing Platform
Description

First-in-class, patented, fully-closed, end-to-end automation platform enabling decentralized production and cost-effective scale-up of personalized skin tissue therapy. Modules include cell isolation, cell expansion, and skin tissue formation, supporting the manufacturing of large personalized skin grafts.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-10
Description

Collaboration agreement signed with RKZ, one of the EU's leading burn centers. RKZ participated in Phase 2 and Phase 3 trials. The agreement sets the stage for establishing CUTISS' first international commercial production facility in the Netherlands once denovoSkin is approved.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-04-14
Description

Strategic partnership to industrialize CUTISS' automated manufacturing solution from engineering development to industrial-grade production. Tecan, a global leader in laboratory automation with Swiss roots, is transitioning CUTISS' denovoCast automation platform to production scale. This collaboration supports bringing denovoSkin to market at scale and expanding into new areas of regenerative medicine.

Strategic tierMajorTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2022-02-01
Description

CUTISS received exclusive global rights to commercialize VitiCell, an MDD CE-marked medical device developed by IBSA Pharma for skin re-pigmentation/autologous cell grafting for vitiligo treatment.

Strategic tierSupportingTypeTechnology or Integration
Description

Collaboration on automation platform development for skin tissue manufacturing. Initial automation development conducted with CSEM and Innosuisse support.

Strategic tierMajorTypeStrategic or Co-development Partner
Description

Leading US burn center that performed the first U.S. compassionate use of denovoSkin in pediatric reconstructive surgery (2024) and published peer-reviewed case report. Authorized by FDA under single patient IND application.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Collaborated on first U.S. compassionate use case for pediatric burn reconstructive surgery alongside Massachusetts General Hospital.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Commercial-stage regenerative medicine company marketing Apligraf and Dermagraft - leading living cell-based skin substitutes for wounds and burns. Directly comparable as a competitor in the bioengineered skin substitute category, though focused on allogeneic off-the-shelf products rather than personalized autologous grafts.

TypeDirect peer
Description

Markets the RECELL System, an autologous cell harvesting device for burns and soft tissue reconstruction. Closely comparable as a personalized, point-of-care skin regeneration technology serving the same burn center and reconstructive surgery customer base as CUTISS.

TypeDirect peer
Description

Develops and commercializes autologous cell therapies including Epicel (cultured epidermal autografts) for severe burns. A direct competitor in the personalized skin graft space for major burns, with established US commercial infrastructure that represents both a benchmark and a competitive threat.

TypeBroad incumbent
Description

Large diversified medical device company with a significant regenerative tissue technologies portfolio including Integra Dermal Regeneration Template for burns and reconstructive surgery. Established incumbent serving the same surgical specialties with broader product breadth.

TypeBroad incumbent
Description

Global medical device company with advanced wound management and skin substitute offerings (including legacy Dermagraft rights via prior acquisitions). Broad incumbent competing in burn and reconstructive surgery with established hospital sales channels.

TypeBroad incumbent
Description

Commercial-stage regenerative medicine company selling dehydrated human amnion/chorion membrane allografts for wound care and surgical recovery. Competes for similar hospital budgets in chronic wounds and surgical applications, though focused on placental tissue rather than personalized skin grafts.

TypeDirect peer
Description

Develops and commercializes NovoSorb biodegradable temporizing matrix for severe burns and reconstructive surgery. Direct comparator as an emerging skin substitute technology targeting the same burn center customer base with a different architectural approach (synthetic dermal scaffold vs. living bilayer).

TypeBroad incumbent
Description

Through its Stratatech subsidiary, develops living skin substitute products including StrataGraft for severe burns. Comparable as a bioengineered skin substitute competitor targeting the same regulatory (orphan drug) and clinical pathway, but with allogeneic rather than autologous manufacturing.

TypeBroad incumbent
Description

Global medical products company with advanced wound care portfolio serving burn centers and wound clinics. Indirect competitor in adjacent advanced wound healing applications, representing both an opportunity for partnership and a competitive channel presence.

TypeOthers
Description

Global leader in laboratory automation and a strategic manufacturing partner to CUTISS for industrializing the denovoCast platform. Included as a strategic ecosystem partner rather than competitor - represents both a key commercialization enabler and a concentration risk through partnership dependency.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors9 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cutiss

Regenerative Medicine / Tissue Engineeringcutiss.swiss

CUTISS is a late-stage clinical Swiss biotech developing personalized bioengineered bilayer skin grafts (denovoSkin™) for severe burns and reconstructive surgery, supported by the denovoCast™ automation platform and a vitiligo device (VitiCell®), serving burn centers and reconstructive surgery hospitals.

What Cutiss does

CUTISS AG is a late-stage clinical TechBio company, spun out of the University of Zurich's Tissue Biology Research Unit in 2017, that develops personalized bioengineered skin grafts for patients requiring skin surgery. Its lead product, denovoSkin™, is a living, bilayer (dermal and epidermal) human skin graft produced from a small patient biopsy and expanded to cover large wound areas, with demonstrated near-scarless regeneration, donor-site sparing, and the ability to grow with pediatric patients. The product is classified as an Advanced Therapy Medicinal Product (ATMP) and has received Orphan Drug Designation from Swissmedic, the EMA, and the FDA for the treatment of burns. The company operates a GMP-certified manufacturing facility in Zurich-Schlieren and is currently running a Phase 3 confirmatory study in adolescent and adult severe burn patients across more than 20 specialized hospitals in Switzerland and 8 EU member states.

The company's strategic moat rests on three reinforcing layers. First, a proprietary tissue-engineering process — including automated cell isolation, expansion, and skin-tissue formation — protected by multiple granted U.S. patents and embodied in the denovoCast™ automation platform, which is being industrialized through a strategic partnership with Tecan. Second, a regulatory moat via Orphan Drug Designation across three jurisdictions and an exclusive global license from IBSA Pharma to commercialize VitiCell®, an MDD CE-marked medical device for autologous cell grafting in vitiligo and hypochromatic post-traumatic scars. Third, a distribution moat built through clinical trial site relationships, compassionate-use engagements with leading U.S. centers such as Massachusetts General Hospital and Shriners Children's Boston, and a collaboration agreement with the Dutch burn center Rode Kruis Ziekenhuis to establish a future international production facility in the Netherlands.

CUTISS is a privately held, pre-revenue company that has raised over CHF 130 million across multiple funding rounds, including a CHF 56 million Series C closed in September 2025. Its go-to-market is enterprise field sales targeting hospital procurement channels for ATMPs, with planned future channels through specialized burn centers and reconstructive surgery departments in Switzerland, the EU, and the United States. The leadership team is led by CEO and co-founder Dr. Daniela Marino; in June 2026, former Tecan Group CEO Dr. Achim von Leoprechting was elected Chairman, succeeding co-founder Prof. Martin Meuli, signaling a deliberate shift toward commercial-scale operating discipline ahead of the expected end-2026 Phase 3 readout and subsequent regulatory submissions.

Cutiss firmographics

Firmographics
Name
Cutiss
Legal name
CUTISS AG
Website
https://cutiss.swiss
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
51–100 employees
Short description
CUTISS is a late-stage clinical Swiss biotech developing personalized bioengineered bilayer skin grafts (denovoSkin™) for severe burns and reconstructive surgery, supported by the denovoCast™ automation platform and a vitiligo device (VitiCell®), serving burn centers and reconstructive surgery hospitals.
Ownership category
akta.pro rank

Cutiss industry classification

Industry
Product category
Regenerative Medicine / Tissue Engineering
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHALAD
Wound Closure & Securement (Sutures, Staples, Tissue Adhesives, Skin Closure Strips)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAAAKAB
Drug Product Fill-Finish & Aseptic Manufacturing Services

Keywords

  • Regenerative skin therapy
  • Bioengineered skin grafts
  • Tissue engineering ATMP
  • Burn wound treatment
  • Personalized cell therapy

Where Cutiss is headquartered

Location

Headquarters

HQ city
Schlieren
HQ country
Switzerland
HQ region
Europe

Offices3 records

Markets served

Cutiss business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Operations, Personnel, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

  1. denovoSkin Product Sales: Once regulatory approval is obtained, the company will generate revenue through the sale of denovoSkin as an ATMP (Advanced Therapy Medicinal Product) to hospitals and burn centers for treatment of severe burns and reconstructive surgery. Revenue will be derived from hospital procurement channels.
  2. VitiCell Commercialization: CUTISS holds exclusive global rights to commercialize VitiCell, an MDD CE-marked medical device for skin re-pigmentation. Revenue will be generated upon EU MDR CE marking approval through dermatology and hospital channels.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Cutiss product offering

Product offering

Core offering

CUTISS develops and manufactures personalized, bioengineered dermo-epidermal (bilayer) human skin grafts (denovoSkin™) classified as Advanced Therapy Medicinal Products (ATMPs), produced from a small patient biopsy and expanded to cover large wound areas for treatment of severe burns and reconstructive surgery. The company operates in-house GMP-certified manufacturing in Zurich and is industrializing a patented closed automation platform (denovoCast™) to enable decentralized, scalable production. CUTISS also holds exclusive global rights to commercialize VitiCell®, a CE-marked medical device for autologous cell grafting in vitiligo patients.

Product overview

CUTISS is a late-stage clinical TechBio company pioneering skin tissue therapeutics and bioengineering. The company's core product is denovoSkin™, a personalized, bio-engineered bilayer (dermal-epidermal) human skin graft for burns and reconstructive surgery. Supporting the core product is denovoCast™, an automation platform for scalable, decentralized production of personalized skin tissue. Additionally, CUTISS commercializes VitiCell®, a CE-marked medical device for skin re-pigmentation in vitiligo patients, licensed from IBSA Pharma. The company operates in-house GMP manufacturing capabilities and is industrializing its automation platform in partnership with Tecan for large-scale production.

Differentiator

Problem solved

Functional benefit

Brands

  • denovoSkin: Personalized bio-engineered dermo-epidermal skin graft for treatment of burns and reconstructive surgery. A living, bilayer skin graft composed of both epidermis and dermis that can be produced from a small patient biopsy.
  • VitiCell
  • denovoCast

Products and services

  • denovoSkin™ Personalized, bioengineered dermo-epidermal (bilayer) human skin graft composed of both dermis and epidermis, manufactured from a small biopsy of the patient's own healthy skin and expanded to produce large quantities of new skin. Classified as an Advanced Therapy Medicinal Product (ATMP) for the treatment of severe burns and reconstructive surgery indications, demonstrating near-scarless regeneration, donor site sparing, and growth with pediatric patients.
  • VitiCell® MDD CE-marked medical device for autologous cell grafting enabling skin re-pigmentation in patients with stable vitiligo and hypochromatic post-traumatic scars. CUTISS holds exclusive global rights to commercialize VitiCell® licensed from IBSA Pharma.
  • denovoCast™ First-in-class, patented, fully-closed, end-to-end automation platform enabling decentralized production and cost-effective scale-up of personalized skin tissue therapy. Modules include cell isolation, cell expansion, and skin tissue formation, supporting the manufacturing of large personalized skin grafts.

Quantifiable outcome

  • Significantly better scar quality than standard of care (STSG) at 3 months, maintained at 12 months
  • +3 more outcomes

Companies that use Cutiss

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Cutiss technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Cutiss partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core, major and supporting.

  • Rode Kruis Ziekenhuis (RKZ) / Red Cross BeverwijkcoreStrategic or Co-development Partner · 10 September 2025Collaboration agreement signed with RKZ, one of the EU's leading burn centers. RKZ participated in Phase 2 and Phase 3 trials. The agreement sets the stage for establishing CUTISS' first international commercial production facility in the Netherlands once denovoSkin is approved.
  • TecancoreTechnology or Integration · 14 April 2025Strategic partnership to industrialize CUTISS' automated manufacturing solution from engineering development to industrial-grade production. Tecan, a global leader in laboratory automation with Swiss roots, is transitioning CUTISS' denovoCast automation platform to production scale. This collaboration supports bringing denovoSkin to market at scale and expanding into new areas of regenerative medicine.
  • IBSA PharmamajorOEM/ Whitelabel/ Licensing Partner · 1 February 2022CUTISS received exclusive global rights to commercialize VitiCell, an MDD CE-marked medical device developed by IBSA Pharma for skin re-pigmentation/autologous cell grafting for vitiligo treatment.
  • CSEMsupportingTechnology or IntegrationCollaboration on automation platform development for skin tissue manufacturing. Initial automation development conducted with CSEM and Innosuisse support.
  • Massachusetts General HospitalmajorStrategic or Co-development PartnerLeading US burn center that performed the first U.S. compassionate use of denovoSkin in pediatric reconstructive surgery (2024) and published peer-reviewed case report. Authorized by FDA under single patient IND application.
  • Shriners Children's Hospital BostonsupportingStrategic or Co-development PartnerCollaborated on first U.S. compassionate use case for pediatric burn reconstructive surgery alongside Massachusetts General Hospital.

Scale indicators7 records

Recent moves8 records

Expansion highlights7 records

Cutiss competitors and assessment

Company assessment

Direct peers

  • Organogenesis Holdings: Commercial-stage regenerative medicine company marketing Apligraf and Dermagraft - leading living cell-based skin substitutes for wounds and burns. Directly comparable as a competitor in the bioengineered skin substitute category, though focused on allogeneic off-the-shelf products rather than personalized autologous grafts.
  • AVITA Medical: Markets the RECELL System, an autologous cell harvesting device for burns and soft tissue reconstruction. Closely comparable as a personalized, point-of-care skin regeneration technology serving the same burn center and reconstructive surgery customer base as CUTISS.
  • Vericel Corporation: Develops and commercializes autologous cell therapies including Epicel (cultured epidermal autografts) for severe burns. A direct competitor in the personalized skin graft space for major burns, with established US commercial infrastructure that represents both a benchmark and a competitive threat.
  • Polynovo Limited: Develops and commercializes NovoSorb biodegradable temporizing matrix for severe burns and reconstructive surgery. Direct comparator as an emerging skin substitute technology targeting the same burn center customer base with a different architectural approach (synthetic dermal scaffold vs. living bilayer).

Broad incumbents

  • Integra LifeSciences: Large diversified medical device company with a significant regenerative tissue technologies portfolio including Integra Dermal Regeneration Template for burns and reconstructive surgery. Established incumbent serving the same surgical specialties with broader product breadth.
  • Smith+Nephew: Global medical device company with advanced wound management and skin substitute offerings (including legacy Dermagraft rights via prior acquisitions). Broad incumbent competing in burn and reconstructive surgery with established hospital sales channels.
  • MiMedx Group: Commercial-stage regenerative medicine company selling dehydrated human amnion/chorion membrane allografts for wound care and surgical recovery. Competes for similar hospital budgets in chronic wounds and surgical applications, though focused on placental tissue rather than personalized skin grafts.
  • Mallinckrodt Pharmaceuticals (Stratatech): Through its Stratatech subsidiary, develops living skin substitute products including StrataGraft for severe burns. Comparable as a bioengineered skin substitute competitor targeting the same regulatory (orphan drug) and clinical pathway, but with allogeneic rather than autologous manufacturing.
  • Convatec Group: Global medical products company with advanced wound care portfolio serving burn centers and wound clinics. Indirect competitor in adjacent advanced wound healing applications, representing both an opportunity for partnership and a competitive channel presence.

Others

  • Tecan Group: Global leader in laboratory automation and a strategic manufacturing partner to CUTISS for industrializing the denovoCast platform. Included as a strategic ecosystem partner rather than competitor - represents both a key commercialization enabler and a concentration risk through partnership dependency.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Cutiss social profiles

Digital presence

Cutiss compliance and trust

Trust signal

Compliance6 records

Cutiss financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cutiss leadership team

Management profile

Number of profiles

Profiles8 records

Cutiss subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Cutiss funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors9 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cutiss M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cutiss

What does Cutiss do?

CUTISS develops and manufactures personalized, bioengineered dermo-epidermal (bilayer) human skin grafts (denovoSkin™) classified as Advanced Therapy Medicinal Products (ATMPs), produced from a small patient biopsy and expanded to cover large wound areas for treatment of severe burns and reconstructive surgery. The company operates in-house GMP-certified manufacturing in Zurich and is industrializing a patented closed automation platform (denovoCast™) to enable decentralized, scalable production. CUTISS also holds exclusive global rights to commercialize VitiCell®, a CE-marked medical device for autologous cell grafting in vitiligo patients.

Is Cutiss a public or private company?

Cutiss is a private company. It is classified as venture growth investor backed and is currently operating.

When was Cutiss founded?

Cutiss was founded in 2017. It employs 51 to 100 people.

Where is Cutiss based?

Cutiss is headquartered in Schlieren, Switzerland, in the Europe region.

How does Cutiss make money?

Two revenue lines are on record. denovoSkin Product Sales are the primary driver. The others are vitiCell Commercialization.

Who are Cutiss's main competitors?

Direct peers on record are Organogenesis Holdings, AVITA Medical, Vericel Corporation and Polynovo Limited. Broad incumbents are Integra LifeSciences, Smith+Nephew, MiMedx Group, Mallinckrodt Pharmaceuticals (Stratatech) and Convatec Group. Tecan Group is listed as an others.

Does Cutiss have an API?

No public API is recorded for Cutiss.

What industry is Cutiss in?

Cutiss's product category is Regenerative Medicine / Tissue Engineering. Its primary akta.pro industry code is HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes), with a secondary code of HLAHALAD, Wound Closure & Securement (Sutures, Staples, Tissue Adhesives, Skin Closure Strips). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
startupticker.chGlobal recognition for Swiss innovatorsSwiss startups Procavea, Treeless, Windtracx, CUTISS, and PolaSight won prizes and accelerator placements, including a €20,000 grant and a ticket to a European and US accelerator program. The companies address healthcare and materials challenges, with CUTISS nominated for the EY World Entrepreneur of the Year 2027.startupticker.chEntrepreneur Of The Year 2026: Die Finalisten stehen festEY announced its finalists for its Entrepreneur of the Year 2026 award, with 13 individuals from nine companies among 70 applicants from 57 firms. Five of the nine finalists are founder-led scale-ups: CUTISS, ofinto, REGENERA, Oviva and PHOENIQS. Winners will be announced and awarded on 23 October 2026 in Zurich.startupticker.chPromising progress for therapies against critical medical needsFour biotech companies reported positive clinical trial milestones for therapies targeting unmet medical needs: iOnctura progressed roginolisib into Phase I/II for myelofibrosis, AL-S Pharma demonstrated positive Phase 2 results for AP-101 in ALS, Aurealis completed Phase 2 for AUP-16 in diabetic foot ulcers, and CUTISS published Phase IIb results for denovoSkin in burn patients. The studies were conducted across multiple European clinical sites, with CUTISS also establishing its manufacturing in Zurich, Switzerland. These developments represent meaningful advances toward addressing significant gaps in treatment for rare and hard-to-treat conditions.McKinsey & CompanyTen years of celebrating tech trailblazers with THE SPARK prizeTHE SPARK, a German digital innovation award co-presented by McKinsey and Handelsblatt, marked its tenth anniversary by awarding first place to Black Semiconductor for its light-based chip communication technology, second place to CUTISS for personalized lab-grown skin, and third place to NEURA Robotics for cognitive robotics. McKinsey research cited in the article projects that Europe's deep tech startup ecosystem could generate up to $1 trillion in enterprise value and one million new jobs by 2030 if commercialization accelerates. The DEI Accelerator Award was presented to MINTD, a global network advancing women in STEM and leadership.Pulse 2.0CUTISS: CHF 56 Million Secured For Advancing Personalized Skin TherapyCUTISS closed a CHF 56 million Series C round, bringing total capital to over CHF 125 million. The funding supports denovoSkin, a personalized skin graft, with a Phase 3 trial ongoing across Switzerland and eight EU states, with first data expected by end of 2026. The company also plans to launch VitiCell, a CE-marked device for vitiligo.Tech.euCUTISS secures €57.9M Series C to advance regenerative skin therapiesCUTISS closed a €57.9M Series C round, bringing total funding to over €129.3M. The funds will advance Phase 3 trials of its denovoSkin bioengineered skin graft, which has orphan drug status. The company also plans to launch VitiCell for vitiligo treatment.BioSpaceCUTISS closes CHF 56M Series C round and signs agreement with leading EU burn centerCUTISS closed a CHF 56M Series C round, bringing total funds to over CHF 125M. The proceeds will fund the Phase 3 trial of denovoSkin™ and prepare for commercialization. The company also signed an agreement with Rode Kruis Ziekenhuis, potentially establishing a production center in the Netherlands.startupticker.chCUTISS raises additional CHF 31 million to support ongoing Phase 3 trialsCUTISS raised an additional CHF 31 million in a Series C round, bringing total funding to over CHF 125 million. The funds will support Phase 3 trials of denovoSkin and prepare for commercialization, with first data expected by end of 2026. The company also plans to launch VitiCell for vitiligo treatment.CutissCUTISS closes CHF 56M Series C round and signs agreement with leading European burn center – CUTISSCUTISS closed a CHF 56M Series C round, bringing total funding to over CHF 125M. The funds will support Phase 3 trials of denovoSkin™ and prepare for commercialization. The company also signed an agreement with Rode Kruis Ziekenhuis for a potential production center in the Netherlands.PR NewswireCUTISS closes CHF 56M Series C round and signs agreement with leading EU burn centerCUTISS closed a CHF 56M Series C round, bringing total funds to over CHF 125M. The proceeds will fund Phase 3 trials of denovoSkin™ and prepare for commercialization. The company also signed an agreement with Rode Kruis Ziekenhuis, potentially establishing a production center in the Netherlands.